{"entity":{"id":"nct06252649","kind":"trial","name":"Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal","aka":["CodeBreaK 301"],"tldr":"A phase 3 trial of Sotorasib, Panitumumab in colorectal cancer, run by Amgen, now recruiting.","summary":"Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation is a phase 3 interventional study registered as NCT06252649 by Amgen, with 450 participants planned, started 2024-07-17 and due to reach its primary completion in 2028-09-25. Interventions recorded: FOLFIRI Regimen, Sotorasib, Panitumumab, Bevacizumab-awwb. Conditions listed: Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06252649","url":"https://clinicaltrials.gov/study/NCT06252649"}],"tags":["ctgov-ingest"],"related":[],"cancers":["colorectal","kras-g12c-colorectal"],"sections":[],"technologies":["kras-inhibitors","monoclonal-antibody"],"targets":[],"drugs":["sotorasib","panitumumab"],"companies":["amgen"],"institutions":[],"pathways":[],"terms":[],"trials":["codebreak-300"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["CodeBreaK 301 is the first-line randomised test of sotorasib and panitumumab with FOLFIRI against FOLFIRI with or without bevacizumab in treatment-naive KRAS G12C-mutated metastatic colorectal cancer. The registry lists 450 participants, a start date of 17 July 2024, recruitment continuing and primary completion due 25 September 2028."],"nct":"NCT06252649","phase":"3","setting":"Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)","sponsor":"Amgen","started":"2024-07-17","startedType":"actual","enrolled":450,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06252649/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"kras-g12c-colorectal","kind":"cancer","name":"KRAS G12C-mutant colorectal cancer","route":"/cancers/kras-g12c-colorectal/"}],"technology":[{"id":"kras-inhibitors","kind":"technology","name":"KRAS & RAS inhibitors","route":"/technologies/kras-inhibitors/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"drug":[{"id":"panitumumab","kind":"drug","name":"Panitumumab","route":"/drugs/panitumumab/"},{"id":"sotorasib","kind":"drug","name":"Sotorasib","route":"/drugs/sotorasib/"}],"company":[{"id":"amgen","kind":"company","name":"Amgen","route":"/companies/amgen/"}],"trial":[{"id":"codebreak-300","kind":"trial","name":"CodeBreaK 300","route":"/trials/codebreak-300/"}]}}